Program
aleniglipron
Also written as “Aleniglipron”, “GSBR-1290” and “GSBR-1290 (Capsule/Tablet)”.
Its studies are mostly in Obesity, led by Structure Therapeutics.
Furthest: phase 3, since Jun 12, 20267 company-led studies, 4 open or runningNext primary completion: Aug 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Structure Therapeutics | 74 open or running | phase 3since Jun 12, 2026 | Jan 25, 2023 | Aug 2027phase 1 · NCT07872033 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 25, 2023First study: phase 2 study in OverweightFirst studyNCT05762471 · 142 enrolled · United States
- May 30, 2023Phase 1 study in Healthy VolunteersNCT05893043 · 18 enrolled · United States
- Nov 14, 2023Phase 1 study in Healthy VolunteersNCT06139055 · 70 enrolled · United States
- Oct 28, 2025Phase 2 study in ObesityNCT07400588 · 58 enrolled · United States
- Jun 12, 20262 phase 3 studies in ObesityPhase 3 reachedNCT07654374, NCT07654361
- Oct 7, 2026Phase 1 study in Hepatic ImpairmentNCT07872033 · 36 planned · United States
Ahead
- Aug 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07872033
- Sep 2028Primary completion: phase 3 study in ObesityNCT07654374
- Sep 2028Primary completion: phase 3 study in ObesityNCT07654361
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07872033Hepatic Impairment · United States | 1 | Not yet recruiting | Aug 2027 | 36 |
| NCT07654374Obesity · United States | 3 | Recruiting | Sep 2028 | 1,100 |
| NCT07654361Obesity · United States | 3 | Recruiting | Sep 2028 | 3,600 |
| NCT07400588Obesity · United States | 2 | Completed | Sep 18, 2026 | 58 |
| NCT06139055Healthy Volunteers · United States | 1 | Active, not recruiting | Mar 2024 | 70 |
| NCT05893043Healthy Volunteers · United States | 1 | Completed | Jun 28, 2023 | 18 |
| NCT05762471Overweight · United States | 2 | Completed | Apr 11, 2024 | 142 |
How it is read
Names in the registry
- “Aleniglipron”, 3 entries
- “aleniglipron”, 3 entries
- “GSBR-1290”, 3 entries
- “GSBR-1290 (Capsule/Tablet)”, 1 entry
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.